Innovation Fuels Rally for Tempus AI: Should You Buy the Stock Today?

Tempus AI (TEM) shares jumped 12.5% in early June, driven by new product launches, including the xM liquid biopsy assay and the EHR integration of Tempus One, and a $200 million AI partnership with AstraZeneca to develop an oncology-focused foundation model. The company's stock has risen 83.8% YTD, outperforming its industry, but it remains unprofitable with a Q1 2025 adjusted EBITDA loss of $16.2 million and trades at a premium with a forward P/S ratio of 7.77.

Analysis

Tempus AI (TEM) has demonstrated significant market momentum, with its stock surging 12.5% in early June and achieving an 83.8% year-to-date increase, substantially outperforming the Medical Info Systems industry's 24.3% rise and the broader Medical sector's 2.7% decline. This rally is primarily fueled by positive investor reaction to strategic innovations, including the launch of the xM liquid biopsy assay for monitoring immunotherapy response and the EHR integration of its generative AI-powered clinical assistant, Tempus One. A pivotal development is the three-year, $200 million data and modeling license agreement with AstraZeneca and Pathos to co-develop a large oncology-focused AI foundation model, utilizing Tempus's 300 petabytes of multimodal data and elevating Tempus's total remaining contract value to over $1 billion. Furthermore, the acquisition of Deep 6 AI is set to expand Tempus's clinical trial matching capabilities and provider connectivity, now exceeding 4,000 connections. Despite these strategic advancements, record revenues, and gross profit growth, Tempus AI remains unprofitable, reporting an adjusted EBITDA loss of $16.2 million in the first quarter of 2025, though this marked an improvement from a $43.9 million loss in the prior year's quarter. The company's stock currently trades at a forward 12-month price-to-sales ratio of 7.77, representing a premium compared to the industry average of 6.09 and peers like iRhythm Technologies (6.28X) and SOPHiA GENETICS (2.55X). Positive technical indicators show the stock trading above its 50-day and 200-day moving averages, suggesting continued upward price momentum.

Key Decisions for Investors

• Given Tempus AI's strong long-term growth prospects driven by genomic data expansion, innovative product launches, and a significant AI partnership with AstraZeneca, current shareholders should consider holding their positions.
• Prospective investors should exercise caution due to the stock's premium valuation relative to peers and its ongoing lack of profitability; awaiting a more favorable entry point or concrete evidence of a path to positive EBITDA may be prudent.
• Investors should closely monitor key catalysts such as the successful execution of the AstraZeneca collaboration, the market adoption and clinical utility of new products like xM and Tempus One, and consistent progress towards achieving profitability.